Group 1 - China National Airlines reported a 3% year-on-year increase in passenger turnover for January 2026, despite a 0.9% decrease in passenger capacity [1] - China National Airlines' cargo capacity decreased by 3.9%, but cargo turnover increased by 4.4% [1] - The cargo load factor improved by 2.8 percentage points to 35.6% [1] Group 2 - Dongfang Chuangye obtained a loan commitment letter from China Minsheng Bank for up to 90 million yuan, intended for share repurchase [2] - China Merchants Port reported a 2.2% year-on-year increase in container throughput for January 2026, totaling 18.083 million TEUs [3] - ST Yigou announced a plan by a major shareholder to reduce holdings by up to 2.5% of the company's shares [4] Group 3 - Southwest Securities plans to raise up to 6 billion yuan through a private placement to supplement its capital [5] - Hanzhong Precision reported a 45.54% year-on-year decline in net profit for 2025, with revenue down 20.32% [6] - SF Holding's total revenue from express logistics, supply chain, and international business grew by 2.22% year-on-year in January 2026 [12] Group 4 - Yunda Holdings reported an 18.01% year-on-year increase in express service revenue for January 2026, amounting to 4.802 billion yuan [18] - High德红外 signed a contract worth 1.851 billion yuan for a complete equipment system, significantly impacting its Q1 2026 performance [19] - SanSheng Guojian received approval for the market launch of its new drug, Anmu Qita monoclonal antibody injection [27] Group 5 - Nanjing Chemical Fiber plans to acquire 100% of Nanjing Gongyi through asset swaps and share issuance [33] - Runze Technology intends to purchase 42.56% of Guangdong Runhui through convertible bonds [35] - ST Xintong's subsidiary signed a server procurement contract worth approximately 400 million yuan [25]

Core Viewpoint - HaiChuang Pharmaceutical (688302) has made significant progress in commercialization, medical insurance access, and research pipeline, with revenue growth and reduced losses as indicated in its performance forecast [1] Group 1: Project Advancement - The company announced on February 1, 2026, that its soft capsule production line for the anti-tumor drug has passed GMP compliance inspection, indicating the core product, Deuteroenzalutamide soft capsules, is now capable of large-scale production, completing the "R&D - Production - Sales" full industry chain [2] Group 2: Business Progress - Deuteroenzalutamide soft capsules were included in the national medical insurance catalog on December 2025, effective from January 1, 2026, which is expected to enhance patient accessibility through a "direct sales + agency" dual-track model; the product was previously approved for market launch in May 2025 and included in the CSCO Prostate Cancer Diagnosis and Treatment Guidelines [3] Group 3: Product Development Progress - The company is focusing on prostate cancer and metabolic diseases, with the oral AR PROTAC drug HP518 having completed Phase I clinical trials, while Phase II trials in China and combination therapy studies are ongoing; HP515, aimed at treating metabolic-associated fatty liver disease (MASH), has entered Phase II clinical trials, with preclinical data on its combination with GLP-1 presented at international conferences [4] Group 4: Performance and Operations - The 2025 performance forecast indicates the company expects revenue between 19 million and 22 million, representing a significant year-on-year increase, with losses narrowing by 24.81% to 37.34%, primarily due to the sales of Deuteroenzalutamide [5] Group 5: Institutional Research - In January 2026, the company hosted a research meeting with 29 institutions, including Foresight Investment and Western Securities, reflecting market interest in its innovative drug pipeline [6]

Group 1 - The core viewpoint of the article highlights the target price increases for listed companies, with notable gains for Huaxia Bank and Xin'an Co., with target price increases of 17.98% and 13.20% respectively [1][2] - On February 13, a total of 18 listed companies received recommendations from brokers, with Huaxia Bank, Pudong Construction, and Changan Automobile each receiving one recommendation [2] - The article mentions that on February 13, brokers provided 7 instances of initial coverage, with Changan Automobile receiving an "Overweight" rating from Shanxi Securities, and Xin'an Co. receiving an "Increase" rating from Guojin Securities [2][4] Group 2 - Huaxia Bank (600015) received a "Outperform" rating from China International Capital Corporation with a target price of 7.94 yuan, reflecting a target price increase of 17.98% [2][4] - Xin'an Co. (600596) was rated "Increase" by Guojin Securities with a target price of 14.24 yuan, indicating a target price increase of 13.20% [2][4] - Other companies receiving initial coverage include Daimai Co. with a "Buy" rating, and Ningbo Huaxiang with a "Buy" rating, both indicating positive outlooks in their respective sectors [4]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xirui (02507) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, Xirui is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Western Securities (002673) noted that Xirui launched the VisionJet G3 product on February 3, with continuous price increases and upgrades in intelligence and comfort [1] - The firm believes that with the gradual acquisition of new orders for better-structured products like VisionJet G3 and SRG7+, the overall product structure will improve year-on-year, enhancing profitability [1]

Group 1 - The core point of the article highlights the intense competition among securities firms during the upcoming Spring Festival holiday, with some firms scheduling numerous roadshows despite the holiday period [1][2][5] - A specific securities firm, Western Securities, has planned a full schedule of roadshows from the evening of New Year's Eve to the end of the holiday, indicating a trend of "internal competition" within the industry [5][17] - Another firm, Kaiyuan Securities, is also actively participating with two to three roadshows daily from the first day of the new year, although they provided a break for analysts on New Year's Eve [19][21] Group 2 - Financial performance data reveals that Western Securities achieved a revenue of 4.335 billion with a year-on-year decline of 2.17%, while profits increased by 70.63% to 1.243 billion [9][21] - However, the research department's income has been on a continuous decline over the past four years, dropping from over 100 million in mid-2022 to only 27.14 million in mid-2025, reflecting issues such as salary cuts, layoffs, and analyst turnover [9][21] - Kaiyuan Securities has also seen a significant drop in research income, with mid-2025 figures falling to less than 60 million, nearly halving compared to previous years [11][23]

Major Announcements - Tianfeng Securities received a notice from the China Securities Regulatory Commission regarding a case of information disclosure violation related to Fujian Yong'an Forestry Group, and the company will cooperate with the investigation [1] - Zhengyuan Wisdom's actual controller was sentenced to three years in prison for manipulating the securities market, but the company's operations remain normal and unaffected [1] - Jialin Jie announced that its actual controller was detained by the Shijiazhuang Public Security Bureau, but the company's control has not changed and operations are normal [2] - Chuangshi Technology's actual controller received a two-year prison sentence for bribery, but this will not impact the company's operations [2] - Xibu Securities received approval from the China Securities Regulatory Commission for its market-making trading business qualification [3] Corporate Actions - Zongshen Power is planning a major asset swap with Longxin General, aiming to resolve competition issues and promote clearer business development [6] - KOTAI Power has decided to terminate its H-share issuance plans due to various factors, but its operations remain stable [4] - Shaanxi Huada has terminated its acquisition of Huajing Microelectronics due to uncertainties in the restructuring plan [5] Contracts and Projects - Gaode Infrared signed a contract worth 1.851 billion yuan for a complete equipment system, which is expected to significantly impact its Q1 2026 performance [7] - Anhui Construction won three engineering projects with a total estimated investment of approximately 64.98 billion yuan [8] - CNOOC Engineering and Saipem formed a joint venture to win a contract worth approximately 4 billion USD for the Qatar NFPS COMP5 project [8] Financial Performance - Fudan Microelectronics reported a net profit of 232 million yuan for 2025, a decrease of 59.42% year-on-year, despite a revenue increase of 10.92% [10] - Yunda Express reported a revenue increase of 18.01% in January 2026, with a total income of 4.802 billion yuan [11] - SF Holding's logistics and supply chain business revenue grew by 2.22% in January 2026, totaling 26.86 billion yuan [13] - China Shenhua's coal sales increased by 9.9% in January 2026, reaching 33.2 million tons [18] Shareholding Changes - Zhang Quantum reduced its stake in Zhang Reading Technology to below 5% after selling 4.3125 million shares [27] - Zhaolong Interconnect announced plans for board members to reduce their holdings by a total of 0.022% [28] - Guanghua New Network's controlling shareholder plans to reduce its stake by up to 3% [29]

Core Viewpoint - Western Securities has received approval from the China Securities Regulatory Commission (CSRC) to conduct market-making trading for listed securities, specifically for stocks on the Beijing Stock Exchange [2] Group 1 - The company will amend its articles of association in accordance with relevant laws and the approval received from the CSRC [2] - Western Securities is required to complete business registration changes and apply for a new securities and futures business license in a timely manner [2] - The company plans to prepare in terms of personnel, business facilities, information systems, and operational locations to ensure the smooth launch of this new business [2]

Core Viewpoint - Western Securities has received approval from the China Securities Regulatory Commission (CSRC) for its market-making business qualifications for listed securities, specifically for trading on the Beijing Stock Exchange [1] Group 1 - The approval is documented in the CSRC's official notice, indicating the regulatory endorsement of the company's market-making capabilities [1] - The qualification is limited to market-making for stocks listed on the Beijing Stock Exchange, suggesting a focused strategy in this specific market [1]

Group 1: Overseas Market Expansion - The company plans to open its first store in Brazil at a shopping center in São Paulo by March 2026, having signed a procurement order for 4 billion coffee beans and plans to build a supply chain factory [2] - The target for Southeast Asia is to increase the number of stores to 10,000 by the end of 2027, with an average annual growth rate of approximately 20%, while optimizing operational efficiency by closing underperforming stores [2] - Since November 2025, the company has opened franchise operations in 16 countries and regions, including Southeast Asia, Japan, South Korea, Australia, and South America, with plans for further expansion [2] Group 2: New Business and IP Development - The company is preparing to launch a theme park, with job postings for roles such as performance coordination and content writing at its Zhengzhou headquarters, indicating a potential rollout of the Snow King IP in physical locations, though specific investment scale and opening dates are yet to be announced [3] - The 福鹿家 brand has approximately 1,200 stores as of August 2025, with a goal to achieve profitability of 1.07 million yuan in 2024, making its performance in 2025 a point of interest for potential growth [3] Group 3: Supply Chain and Operational Optimization - The company is enhancing its global supply chain, with a production base in Hainan set to commence operations in the first half of 2025, and plans to extend upstream to improve the standardization of agricultural product partnerships [4] - Future focus will be on cost control and improving franchisee efficiency [4] Group 4: Institutional Perspectives - There is a divergence in institutional views on the company; UBS downgraded its rating to "neutral" in January 2026, citing risks of declining gross margins, while domestic institutions like Guotai Junan and Western Securities remain optimistic about the company's overseas expansion potential [5]

证券代码：002673 证券简称：西部证券 公告编号：2026-012 西部证券股份有限公司 关于上市证券做市交易业务资格获批的公告 公司将按照有关法律法规和上述批复要求，修改公司章程，按时 完成工商变更登记并申请换发经营证券期货业务许可证。公司将在人 员、业务设施、信息系统和经营场所等方面做好准备工作，加强信息 技术安全管理及业务动态风险监测，切实保障该项业务顺利开展。 特此公告。 西部证券股份有限公司董事会 2026年2月13日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 西部证券股份有限公司（以下简称"公司"）于近日收到中国证 券监督管理委员会（以下简称"中国证监会"）出具的《关于核准西 部证券股份有限公司上市证券做市交易业务资格的批复》（证监许可 〔2026〕273号），中国证监会核准公司上市证券做市交易（限于北 京证券交易所股票做市交易）业务资格。 ...